Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis.

Terziroli Beretta-Piccoli, Benedetta; Buescher, Gustav; Dalekos, George; Zachou, Kalliopi; Geerts, Anja; Semmo, Nasser; Kolev, Mirjam; De Martin, Eleonora; Janik, Maciej K; Madaleno, João; Lalosevic Stojkovic, Milica; Dumortier, Jérôme; Vanwolleghem, Thomas; Schregel, Ida; Steinmann, Silja; Lacaille, Florence; Sebode, Marcial (2023). Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis. (In Press). Journal of autoimmunity, 140(103113), p. 103113. Elsevier 10.1016/j.jaut.2023.103113

[img]
Preview
Text
1-s2.0-S0896841123001221-main.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (550kB) | Preview

BACKGROUND AND AIMS

There is little data on the hepatic efficacy and safety of immunomodulatory drugs used in patients with autoimmune hepatitis (AIH), despite their established use in dermatology, rheumatology and inflammatory bowel diseases (IBD). Our aim was to collect real-life data on the experience of expert centres in treating AIH patients with these drugs, considered unconventional for AIH management.

METHODS

Online survey among hepatology centres being part of the European Reference Network on Hepatological Diseases (ERN RARE-LIVER).

RESULTS

25 AIH patients have been reported. Ten were female, median age at diagnosis was 28 years; median follow-up was 17 months. All had initially received AIH-standard treatment. AIH-unconventional treatment was initiated for concomitant autoimmune diseases in 15 cases: nine for IBD (five vedolizumab and four ustekinumab), and one each for following diseases: autoinflammatory syndrome (tocilizumab), chronic urticaria (omalizumab), rheumatoid arthritis (abatacept), psoriasis (guselkumab), psoriatric arthritis (secukinumab, followed by ustekinumab) and alopecia (ruxolitinib). Three patients were treated with immunomodulatory drugs for side effects of previous treatments, including two patients with IBD treated with vedolizumab and ustekinumab, respectively, and one treated with belimumab. At the end of follow-up, 13 patients were in complete biochemical response, the patient on omalizumab had a relapse, and four patients with concomitant IBD had insufficient response. Seven patients were treated for lack of biochemical remission, of whom six with belimumab, all initially reaching complete biochemical response, but five relapsing during follow-up; and one with secukinumab, having concomitant rheumatoid arthritis and ankylosing spondylitis, reaching complete biochemical response. Only the patient on abatacept received unconventional treatment as monotherapy. Side effects were reported in two patients on belimumab: one recurrent soft tissue infections, one fatigue and arthralgia.

CONCLUSION

Among 25 AIH patients who were treated with immunomodulatory drugs for different reasons, the majority had a fovorable course, relapse was frequent in difficult-to-treat patients who received belimumab, and four with concomitant IBD had insufficient response.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine

UniBE Contributor:

Semmo, Nasser, Kolev, Mirjam

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0896-8411

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

18 Sep 2023 15:53

Last Modified:

19 Sep 2023 09:43

Publisher DOI:

10.1016/j.jaut.2023.103113

PubMed ID:

37716078

BORIS DOI:

10.48350/186365

URI:

https://boris.unibe.ch/id/eprint/186365

Actions (login required)

Edit item Edit item
Provide Feedback